NCT04415944 2026-03-19
HIPEC
Wake Forest University Health Sciences
Phase 2 Completed
Clinical Trials
226 trialsNCT05763199 2026-03-12
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
University of California, Davis
Phase 2 Active not recruiting
NCT07454018 2026-03-06
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT06240598 2026-02-27
A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06890338 2026-02-24
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
Phase 2 Recruiting
NCT07303894 2026-01-29
A Study of Isoquercetin in People With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT01439659 2026-01-16
Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07341100 2026-01-14
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 2 Not yet recruiting
NCT06173037 2026-01-07
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
RemeGen Co., Ltd.
Phase 2 Completed
NCT06690775 2025-12-23
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
TORL Biotherapeutics, LLC
Phase 2 Recruiting
NCT07265739 2025-12-11
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
Massachusetts General Hospital
Phase 2 Not yet recruiting
NCT04644289 2025-10-03
WoO
AGO Research GmbH
Phase 2 Recruiting
NCT07171528 2025-09-12
KOV-02S
National Cancer Center, Korea
Phase 2 Recruiting
NCT05335993 2025-07-10
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
CanariaBio Inc.
Phase 2 Active not recruiting
NCT05563272 2025-07-10
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2 Terminated
NCT02122185 2025-06-08
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
Phase 2 Active not recruiting
NCT06638931 2025-05-28
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT02644369 2025-03-26
INSPIRE
University Health Network, Toronto
Phase 2 Active not recruiting
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT02124421 2024-11-19
CRS/HIPEC
Mercy Medical Center
Phase 2 Active not recruiting
NCT04377087 2024-08-20
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
University of Pittsburgh
Phase 2 Terminated
NCT04807166 2024-07-03
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Active not recruiting
NCT03093155 2024-05-14
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Yale University
Phase 2 Completed
NCT01439490 2024-05-06
FES-PET to Determine ER-expression in Epithelial Ovarian Cancer
University Medical Center Groningen
Phase 2 Completed
NCT05489926 2024-01-26
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT02834975 2023-11-07
Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
University of Miami
Phase 2 Terminated
NCT05272462 2023-10-05
Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer
Loyola University
Phase 2 Unknown
NCT00112957 2023-10-04
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Ludwig Institute for Cancer Research
Phase 2 Completed
NCT01164995 2023-09-07
M10MKO
The Netherlands Cancer Institute
Phase 2 Completed
NCT00993655 2023-08-28
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT01891344 2023-06-12
ARIEL2
pharmaand GmbH
Phase 2 Completed
NCT03824704 2023-06-12
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
pharmaand GmbH
Phase 2 Terminated
NCT04519151 2023-06-08
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sheba Medical Center
Phase 2 Recruiting
NCT05877911 2023-05-26
Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT04670978 2023-04-25
Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Shandong University
Phase 2 Unknown
NCT00538031 2023-04-21
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
City of Hope Medical Center
Phase 2 Completed
NCT03321188 2023-02-06
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
University of Kansas Medical Center
Phase 2 Unknown
NCT00373217 2022-09-21
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
University of Virginia
Phase 2 Terminated
NCT04015739 2022-08-17
BOLD
ARCAGY/ GINECO GROUP
Phase 2 Unknown
NCT05422183 2022-06-16
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Zhongda Hospital
Phase 2 Unknown
NCT02900560 2022-06-10
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Translational Research in Oncology
Phase 2 Terminated
NCT02107937 2022-05-04
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Completed
NCT05158062 2022-04-26
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT01551745 2021-10-19
Salvage Ovarian FANGâ„¢ Vaccine + Bevacizumab
Gradalis, Inc.
Phase 2 Completed
NCT01853644 2021-10-12
TIVO
Northwestern University
Phase 2 Completed
NCT04983550 2021-07-30
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT04834544 2021-05-03
A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care
Peking University Third Hospital
Phase 2 Recruiting
NCT04846842 2021-04-19
A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Lee's Pharmaceutical Limited
Phase 2 Unknown
NCT03025477 2021-02-11
CHIMOVIP
Groupe Hospitalier Diaconesses Croix Saint-Simon
Phase 2 Recruiting
NCT01146795 2021-02-09
Neoadjuvant Therapy for Ovarian Cancer
Columbia University
Phase 2 Completed